644968-75-2

Upstream product

• 644967-79-3 5-chlorospiro[1-benzofuran-2,4'-piperidine]-1'-carboxylic acid 1,1-dimethylethyl ester 
• 460047-81-8 N-{4-methoxy-2-[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide 
• 71916-97-7 5-chloro-2,3-dihydrospiro 
• 58469-06-0 N-(2-hydroxy-4-methoxyphenyl)acetamide 
• 1996-30-1 2-bromo-4-chloro-1-fluorobenzene 
• 704-14-3 3-methoxy-6-nitro-phenol 
• 1055710-50-3 C₁₇H₂₃ClFNO₃ 
• 147804-30-6 1-oxa-6-aza-spiro-[2.5]octane-6-caboxylic acid tert-butyl ester 

Downstream Products

• 1003567-22-3 methyl (4-acetylamino-5-{[(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}phenoxy)acetate 

Relevant academic research and scientific papers

Spirocyclic compounds, potent CCR1 antagonists

Conformationally constrained spirocycles (17-23) and (31-36) were synthesised. In vitro data revealed that these compounds are CCR1 antagonists with sub-nanomolar potency. In a functional assay 22, 23 and 36 inhibited CCR1 mediated chemotaxis with an ICs

NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES

The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t and R9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.